Pregnant Women Undergoing Cesarean DeliveryPhase 4NCT07078942
Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Pregnant Women Undergoing Cesarean Section
A Phase 4 study testing Tranexamic Acid in people with Pregnant Women Undergoing Cesarean Delivery, run by Chulalongkorn University at 1 site in Thailand.
Trial summary
The purpose of this study is to asses the effect of preoperative prophylactic intravenous tranexamic acid on perioperative blood loss in pregnant women undergoing cesarean section Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pregnant Women Undergoing Cesarean Delivery
- What is being tested?
- Tranexamic Acid
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 98 participants
- Where
- 1 siteThailand
- Study dates
- 20 Jul 2025to 31 Dec 2026
- Phase
- Phase 4
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- pregnant women with gestational age 37-42 weeks
- undergoing cesarean delivery with indication as follows: placenta previa, severe preeclampsia, myoma uteri, fetal macrosomia, polyhydramnios, grand multiparity ≥ 5 deliveries, prolonged labor, etc.
Who cannot join
- history of allergy to tranexamic acid
- history of venous thromboembolism (Deep vein thrombosis, Pulmonary embolism)
- history of arterial thrombosis (Myocardial infarction, Stroke)
- history of seizure, convulsion
- have underlying of cardiovascular, renal or liver disease
- using of antiplatelet or anticoagulant within 1 week before operation
Show all 11Show fewer
- placenta accreta spectrum
- abruptio placenta
- Eclampsia or HELLP (Hemolysis Elevated Liver Low Platelet) syndrome
- Failed operative vaginal delivery
- Multifetal gestation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Thailand1 site
Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University
Bangkok, Bangkok, 10330
Vorapong Phupong, M.D., 026492115, vorapong.p@chula.ac.th
Thawit Suesakulpaisal, M.D.
About this study
Official title: Effect of Preoperative Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Pregnant Women Undergoing Cesarean Section : A Randomized Controlled Trial
The purpose of this study is to asses the effect of preoperative prophylactic intravenous tranexamic acid on perioperative blood loss in pregnant women undergoing cesarean section
- Being tested
- Tranexamic Acid, Placebo
- Keywords
- tranexamic acid, blood loss, pregnant women, cesarean delivery
- Medical subject headings
- Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tranexamic AcidDrug
Tranexamic Acid 1 g intravenous preoperation
PlaceboOther
normal saline 20 ml intravenous preoperation
| Study group | Role | What they receive |
|---|---|---|
| Tranexamic acid | Active comparator | Tranexamic acid (1 g) 20 ml intravenous preoperation Receives: Drug: Tranexamic Acid |
| Placebo | Placebo comparator | Normal saline 20 ml intravenous preoperation Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood loss
blood loss in ml
Measured: From enrollment to the end of operation
Secondary outcomes (4)
early postpartum hemorrhage
percentage of early postpartum hemorrhage
Measured: From starting operation to 24-hour postoperation
delayed postpartum hemorrhage
percentage of delayed postpartum hemorrhage
Measured: From starting operation to 6 weeks postpartum
Adverse effects
percentage of adverse effects
Measured: from enrollment to 6 weeks postpartum
Neonatal outcomes
Apgar scores (0 is the minimum value and 10 is maximum value, and higher scores mean a better outcome)
Measured: from starting operation to 10 minutes after birth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2025
- Study start20 Jul 2025 (estimated)
- Primary completion31 Jul 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Pregnant Women Undergoing Cesarean DeliveryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 98 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chulalongkorn University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Vorapong Phupong, Chulalongkorn University
- Investigators
- Vorapong Phupong, M.D., Study director, Chulalongkorn University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07078942
- Sponsor's protocol ID
- 0127/68
- Other IDs
- COA 0685/2025
- Status last verified
- Jul 2025
- First submitted
- 14 Jul 2025
- Last updated
- 28 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Waiting for the permission from IRB
Publications
Sentilhes L, Senat MV, Le Lous M, Winer N, Rozenberg P, Kayem G, Verspyck E, Fuchs F, Azria E, Gallot D, Korb D, Desbriere R, Le Ray C, Chauleur C, de Marcillac F, Perrotin F, Parant O, Salomon LJ, Gauchotte E, Bretelle F, Sananes N, Bohec C, Mottet N, Legendre G, Letouzey V, Haddad B, Vardon D, Madar H, Mattuizzi A, Daniel V, Regueme S, Roussillon C, Benard A, Georget A, Darsonval A, Deneux-Tharaux C; Groupe de Recherche en Obstetrique et Gynecologie. Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. N Engl J Med. 2021 Apr 29;384(17):1623-1634. doi: 10.1056/NEJMoa2028788.
PubMed 33913639Pacheco LD, Clifton RG, Saade GR, Weiner SJ, Parry S, Thorp JM Jr, Longo M, Salazar A, Dalton W, Tita ATN, Gyamfi-Bannerman C, Chauhan SP, Metz TD, Rood K, Rouse DJ, Bailit JL, Grobman WA, Simhan HN, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery. N Engl J Med. 2023 Apr 13;388(15):1365-1375. doi: 10.1056/NEJMoa2207419.
PubMed 37043652Cheema HA, Ahmad AB, Ehsan M, Shahid A, Ayyan M, Azeem S, Hussain A, Shahid A, Nashwan AJ, Mikus M, Lagana AS. Tranexamic acid for the prevention of blood loss after cesarean section: an updated systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol MFM. 2023 Aug;5(8):101049. doi: 10.1016/j.ajogmf.2023.101049. Epub 2023 Jun 11.
PubMed 37311484Angolile CM, Max BL, Mushemba J, Mashauri HL. Global increased cesarean section rates and public health implications: A call to action. Health Sci Rep. 2023 May 18;6(5):e1274. doi: 10.1002/hsr2.1274. eCollection 2023 May.
PubMed 37216058